Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 4Phase 1 4Phase 4 1Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5NET 4Endocrine 4Gastrointestinal 2Breast 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Imiquimod 15Aminolevulinic Acid 8Fluorouracil 6Diclofenac 63-ingenyl angelate 6Nivolumab 5Cryotherapy 5tirbanibulin 4methyl 5-aminolevulinate 4Sirolimus 4denileukin diftitox 3aldesleukin 3Photochemotherapy 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Tacrolimus 2Prednisone 2Ointments 2Methotrexate 2Immune Checkpoint Inhibitors 2HhAntag691 2Gels 2Cyclosporine 2Cryosurgery 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Everolimus × Dermatologic × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡